Delayed
Nasdaq
17:55:50 10/05/2024 BST
|
5-day change
|
1st Jan Change
|
3.501
USD
|
-1.93%
|
|
-8.83%
|
-84.06%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
9.505
|
23.47
|
26.21
|
4.979
|
6.553
|
6.991
|
-
|
-
|
Enterprise Value (EV)
1 |
9.505
|
23.47
|
26.21
|
4.979
|
6.553
|
6.991
|
6.991
|
6.991
|
P/E ratio
|
-1.04
x
|
-1.4
x
|
-0.66
x
|
-0.3
x
|
-0.71
x
|
-0.48
x
|
-0.98
x
|
-1.32
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1.68
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1.68
x
|
EV / EBITDA
|
-
|
-2,379,569
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-1,257,254
x
|
-2,530,275
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
4.21
|
7.89
|
15.8
|
27.9
|
298
|
1,958
|
-
|
-
|
Reference price
2 |
2,256
|
2,976
|
1,664
|
178.2
|
21.97
|
3.570
|
3.570
|
3.570
|
Announcement Date
|
30/03/20
|
31/03/21
|
29/03/22
|
31/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
4.156
|
EBITDA
|
-
|
-9.864
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-8.555
|
-9.868
|
-32.73
|
-11.05
|
-8.234
|
-16.24
|
-18.4
|
-16.02
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-385.48%
|
Earnings before Tax (EBT)
1 |
-8.394
|
-9.851
|
-32.47
|
-11.05
|
-7.711
|
-16.24
|
-18.4
|
-16.02
|
Net income
1 |
-8.394
|
-9.851
|
-32.47
|
-11.05
|
-7.711
|
-16.24
|
-18.4
|
-16.02
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-385.48%
|
EPS
2 |
-2,160
|
-2,128
|
-2,528
|
-600.8
|
-31.04
|
-7.425
|
-3.630
|
-2.695
|
Free Cash Flow
|
-7.56
|
-9.276
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/20
|
31/03/21
|
29/03/22
|
31/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-3.802
|
-3.212
|
-
|
-2.862
|
-2.917
|
-2.555
|
-1.539
|
-1.236
|
-2.117
|
-3.341
|
-3.507
|
-3.23
|
-3.644
|
-3.956
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-3.799
|
-3.211
|
-
|
-2.861
|
-2.917
|
-2.549
|
-1.407
|
-1.106
|
-1.972
|
-3.226
|
-3.507
|
-3.23
|
-3.644
|
-3.956
|
Net income
1 |
-3.799
|
-3.211
|
-2.722
|
-2.861
|
-2.917
|
-2.549
|
-1.407
|
-1.106
|
-1.972
|
-3.226
|
-3.507
|
-3.23
|
-3.644
|
-3.956
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-240.0
|
-64.00
|
-176.0
|
-176.0
|
-176.0
|
-72.80
|
-12.00
|
-4.000
|
-6.400
|
-8.640
|
-2.400
|
-1.645
|
-1.770
|
-1.185
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/11/21
|
29/03/22
|
16/05/22
|
11/08/22
|
10/11/22
|
31/03/23
|
15/05/23
|
14/08/23
|
13/11/23
|
28/03/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-7.56
|
-9.28
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/20
|
31/03/21
|
29/03/22
|
31/03/23
|
28/03/24
|
-
|
-
|
-
|
Last Close Price
3.57
USD Average target price
32.5
USD Spread / Average Target +810.36% Consensus |
1st Jan change
|
Capi.
|
---|
| -84.06% | 6.99M | | +18.05% | 47.02B | | +48.77% | 41.86B | | +0.48% | 41.76B | | -4.27% | 28.8B | | +11.81% | 26.05B | | -22.03% | 19.15B | | +4.55% | 12.55B | | +29.31% | 12.34B | | -3.91% | 11.82B |
Other Biotechnology & Medical Research
|